13FGuru
Sign in with Google Sign in with Discord

NYSE · Health Care

Merck & Co. Inc. MRK

Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands.

Sources StockAnalysis company profile stockanalysis.com
Pharma

Company profile

Business mix

  • It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair.
  • The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products.
  • It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types.
  • The company was founded in 1891 and is headquartered in Rahway, New Jersey.

Current key questions

  • Can the company's products, services, or pipeline expand adoption within drug manufacturers - general?
  • How do reimbursement, regulation, clinical data, patents, and commercial execution affect growth?
  • Can margins and cash flow improve while funding research, manufacturing, or go-to-market investment?
Holders 6 Current sample portfolio
Public mentions 0 Videos / interviews / letters
Valuation snapshot
PE 33.78 FCF 4.73% Buyback 1.79%
2026-06-07

Current firm holders

Firm Weight Value Filing period
Oakmark / Harris Associates Bill Nygren 2.0% $1.5B 2026-03-31
Smead Capital Management 6.5% $297.3M 2026-03-31
Gotham Asset Management Joel Greenblatt 0.2% $60.9M 2026-03-31
Kahn Brothers Group 4.8% $27.3M 2026-03-31
Fairfax Financial Prem Watsa 1.1% $20.8M 2026-03-31
Semper Augustus Investments Group Christopher Bloomstran 0.6% $5.4M 2026-03-31

Recent trading changes over the last 3 quarters

Last 1 quarters Last 2 quarters Last 3 quarters Last 4 quarters
Net buyers 3 Last 3 13F filing periods
Net reducers 3 Last 3 13F filing periods
Unchanged holders 1 Share count unchanged
Increase amount $392.5M Estimated from net added shares
Reduction amount $218.5M Estimated from net reduced shares
Net share change / base shares +7.1% +1,053,456 / 14,736,247
Bridgewater Associates Ray Dalio 3 filing periods
13F 2025-09-30 Filed 2025-11-13
Major reduction Shares -55.3% 13F value change -$48.0M
13F 2025-12-31 Filed 2026-02-13
Major reduction Shares -39.6% 13F value change -$10.5M
13F 2026-03-31 Filed 2026-05-15
Sold out Shares -100.0% 13F value change -$32.7M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 1,150,722 Last 3 periods -1,150,722 (-100.0%) Total shares 0 Value $0
Gotham Asset Management Joel Greenblatt 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Major increase Shares 23.6% 13F value change +$11.8M
13F 2025-12-31 Filed 2026-02-17
Major reduction Shares -24.5% 13F value change -$2.6M
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 13.2% 13F value change +$13.8M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 479,081 Last 3 periods +27,470 (+5.7%) Total shares 506,551 Value $60.9M
Fairfax Financial Prem Watsa 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-17
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-15
Unchanged Shares 0.0% 13F value change $0
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 172,900 Last 3 periods +0 (0.0%) Total shares 172,900 Value $20.8M
Oakmark / Harris Associates Bill Nygren 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Minor increase Shares 7.6% 13F value change +$101.7M
13F 2025-12-31 Filed 2026-02-17
Major increase Shares 43.4% 13F value change +$658.5M
13F 2026-03-31 Filed 2026-05-15
Minor reduction Shares -12.2% 13F value change +$4.6M
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 9,131,318 Last 3 periods +3,235,615 (+35.4%) Total shares 12,366,933 Value $1.5B
Semper Augustus Investments Group Christopher Bloomstran 3 filing periods
13F 2025-09-30 Filed 2025-11-14
Unchanged Shares 0.0% 13F value change $0
13F 2025-12-31 Filed 2026-02-17
Unchanged Shares 0.0% 13F value change $0
13F 2026-03-31 Filed 2026-05-15
Minor increase Shares 0.4% 13F value change +$690,834
Settlement As of 13F 2026-03-31 · Filed 2026-05-15
Base shares 44,443 Last 3 periods +190 (+0.4%) Total shares 44,633 Value $5.4M
Smead Capital Management 3 filing periods
13F 2025-09-30 Filed 2025-11-10
Minor reduction Shares -7.1% 13F value change -$3.9M
13F 2025-12-31 Filed 2026-02-09
Minor reduction Shares -6.5% 13F value change +$44.1M
13F 2026-03-31 Filed 2026-05-14
Minor reduction Shares -12.9% 13F value change -$1.5M
Settlement As of 13F 2026-03-31 · Filed 2026-05-14
Base shares 3,267,318 Last 3 periods -795,920 (-24.4%) Total shares 2,471,398 Value $297.3M
Kahn Brothers Group 3 filing periods
13F 2025-09-30 Filed 2025-11-12
Minor reduction Shares -11.6% 13F value change -$2.4M
13F 2025-12-31 Filed 2026-02-12
Minor reduction Shares -0.8% 13F value change +$8.9M
13F 2026-03-31 Filed 2026-05-08
Major reduction Shares -47.2% 13F value change -$17.9M
Settlement As of 13F 2026-03-31 · Filed 2026-05-08
Base shares 490,465 Last 3 periods -263,177 (-53.7%) Total shares 227,288 Value $27.3M

Recent mentions

No public mentions.